Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 6, 2026Open Access

Dissecting the multiple myeloma survival niche to improve novel treatment strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMara John

Discussion

Loading...

Member takes

Overview

Randomized trial investigates the tumor microenvironment and immune response in multiple myeloma, suggesting novel therapeutic strategies.

Key Points

  • This study aims to explore the relationship between high-risk genomic alterations in multiple myeloma and T-cell dysfunction in the tumor microenvironment.
  • Investigated tumor microenvironment in the bone marrow of multiple myeloma patients depending on risk status and presence of extramedullary disease.
  • Used flow cytometry (n=162), single-cell RNA sequencing (n=19), and liquid chromatography-mass spectrometry (n=49) to analyze immune cells and metabolites.
  • Performed spatial transcriptomics and scRNAseq on 14 EMD samples to examine immune cell distribution.
  • Found a decrease in CD3e+ T cells in high-risk patients compared to standard-risk patients and a reduction of naïve T cells post-treatment.
  • Untreated high-risk patients exhibited lower levels of glutamine and arginine metabolites.
  • Identified exhausted TIM3+/PD-1+ T cells near plasma cells and functional CD8+ T cells in specific niches of EMD, correlating with responses to bispecific antibody therapy.

Cite This Study

Mara John (2025) studied this question.

synapsesocial.com/papers/6a23b8f271a5da9775e74f45https://doi.org/10.25972/opus-42115
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma2025
  2. 2Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models2025
  3. 3Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy2025
  4. 4Multi-omics reveals immune features in immune and non-immune cells, an IFN-γ/IFN-α-B2M positive feedback loop, and targeted metabolic therapy in multiple myeloma2025
  5. 5Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma2025